The FDA has approved a new drug called Vyvgart (efgartigimod alfa) for adults with a specific type of generalized myasthenia gravis (gMG). This condition causes muscle weakness that can affect daily activities like walking, talking, and breathing. Vyvgart is for patients who test positive for a certain antibody called anti-acetylcholine receptor (AChR). It works by blocking a protein that normally keeps antibodies in the blood longer. By doing this, Vyvgart helps lower the level of harmful antibodies that attack the muscles.
Vyvgart is given as an intravenous infusion once a week for 4 weeks. After that, your doctor will decide if more cycles are needed based on how you are doing. This approval gives patients a new targeted treatment option. It may help those who have not responded well to other therapies.
However, Vyvgart is not for everyone with myasthenia gravis. It is only for adults who are AChR antibody positive. Also, because Vyvgart lowers antibody levels, live vaccines are not recommended during treatment. This is a temporary effect.
If you have generalized myasthenia gravis, talk to your doctor about whether Vyvgart might be right for you. Your doctor can help you understand the benefits and risks based on your specific health situation.